Ibrutinib (Ibrutinib)
Overview of Ibrutinib
Ibrutinib is an inhibitor of Bruton�s tyrosine kinas (BTK), indicated for the treatment of patients with mantle cell lymphoma (MCL).The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1Hpyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one.
Indication of Ibrutinib
Ibrutinib is primarily indicated in conditions like Mantle Cell Lymphoma.
Contraindication of Ibrutinib
No data regarding the contra indications of Ibrutinib is available.
Side Effects of Ibrutinib
No data regarding the side effects produced by Ibrutinib is available
Precautions of Ibrutinib
Hemorrhage, Infections, Myelosuppression, Renal Toxicity, Second Primary Malignancies including skin cancers, and other carcinomas, Embryo-Fetal Toxicity: